micromoles to 300 millimoles liter preferably 10 to 200 millimoles liter the catalytic antibodies of the present invention will also be of use in those situations where a high degree of sensitivity is required for example blotting assays including western southern and northern blotting assays as well as dot blots and other nucleic acid hybridisation assays a further potential use of the catalytic antibodies is in non separation immunoassay formats in conjunction with a luminol label for example binding of a luminol labeled drug to a specific drug antibody would prevent interaction between the luminol label and added catalytic antibody however in the presence of the drug relatively less luminol labeled drug would be bound to the drug antibody and the luminol label would interact effectively with the catalytic antibody the degree of modulation of the light emission would give an indication of drug concentration another further use for the catalytic antibodies described above is in enhanced peroxidase dpd oxidant chemiluminescent reactions where it is believed that the catalytic antibody will further increase the light output preparation of a catalytic antibody capable of increasing light output from a chemiluminescent reaction luminol aldrich milwaukee wis was purified by recrystallization from sodium hydroxide as described previously ham g et al anal lett 12 535 541 1979 apa kodak rochester n y was conjugated to keyhole limpet hemocyanin klh and bovine serum albumin bsa using a pierce imject immunogen edc conjugation kit with bsa and klh pierce rockford ill following the manufacturers 39 instructions monoclonal antibodies were produced by babco richmond calif 94806 following standard protocols an elisa immobilized apa klh or apa bsa capture antigen.